Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors

Simona Di Giambenedetto, Alessanra Bacarelli, Carmen Pinnetti, Manuela Colafigli, Mattia Prosperi, Giorgio Gatti, Roberto Cauda, Andrea De Luca

Research output: Contribution to journalArticle

Abstract

The aim of this study was to establish the prevalence and predictors of genotypic resistance of HIV-1 to lopinavir and fosamprenavir from patients failing protease inhibitors (PI)-based regimens. We selected 643 HIV-1-infected patients with available treatment history who underwent genotypic resistance assays for virological failure from a clinical site and from the Stanford database. According to the genotypic resistance interpretation of the Stanford algorithm, proportions of viruses showing full susceptibility to fosamprenavir and lopinavir were 32% and 34%, respectively (p =ns). Proportions of viruses fully susceptible to lopinavir/r and fosamprenavir/r according to the Agence Nationale pour la Recherche sur le SIDA (ANRS) algorithm, were 81% and 81%, respectively. According to the Rega algorithm, proportions of viruses showing full susceptibility to fosamprenavir/r and lopinavir were 80% and 70%, respectively (p

Original languageEnglish
Pages (from-to)813-818
Number of pages6
JournalScandinavian Journal of Infectious Diseases
Volume39
Issue number9
DOIs
Publication statusPublished - 2007

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Fingerprint Dive into the research topics of 'Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors'. Together they form a unique fingerprint.

  • Cite this